- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941011
Hyaluronic Acid Barrier in Parotidectomy
The purpose of this study is to evaluate the efficacy of AxoGuard HA+ (hyaluronic acid nerve protector) in preventing Frey syndrome following parotidectomy. A parotidectomy is a surgical procedure to remove all or part of the parotid gland, the largest salivary gland located near the ear and jaw. The specific aims are to determine whether placement of AxoGuard HA+ during parotidectomy can significantly reduce both clinical and subclinical incidence of Frey syndrome compared to standard surgical technique alone.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Bailey Swaffar
- Phone Number: 717-531-1614
- Email: bswaffar@pennstatehealth.psu.edu
Study Contact Backup
- Name: Shwetha Srikanth
- Phone Number: 287291 717-531-0003
- Email: ssrikanth@pennstatehealth.psu.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults (≥18 years) undergoing parotid surgery for benign parotid masses
- Able to provide informed consent for study participation.
Exclusion Criteria:
- Pregnant or breastfeeding patients
- Known allergy to hyaluronic acid products
- Previous parotid surgery or radiation
- Patients with known sensitivity to porcine, alginate, or hyaluronate materials.
- Known allergy to iodine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Parotidectomy
Parotidectomy - Standard of Care |
A parotidectomy is a surgical procedure to remove all or part of the parotid gland, the largest salivary gland located near the ear and jaw. |
|
Experimental: Parotidectomy with Axoguard HA+ Nerve Protoector
Parotidectomy - With use of nerve protector |
AxoGuard HA+ nerve protector is an FDA-approved device available for clinical use, but its specific efficacy in preventing Frey syndrome following parotidectomy has not been systematically evaluated in controlled trials. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of subjects with positive Starch-Iodine test
Time Frame: 3 months post-op
|
3 months post-op
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of subjects with positive Starch-Iodine test
Time Frame: 12 months post-op
|
12 months post-op
|
|
|
Number of subject experiencing a reduction in clinically reported symptoms of Frey Syndrome
Time Frame: 1 month pot-op
|
Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing. |
1 month pot-op
|
|
Number of subject experiencing a reduction in clinically reported symptoms of Frey Syndrome
Time Frame: 3 months pot-op
|
Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing. |
3 months pot-op
|
|
Number of subject experiencing a reduction in clinically reported symptoms of Frey Syndrome
Time Frame: 12 months pot-op
|
Facial sweating, flushing, warmth/burning sensation, tingling/prickling, itching, and symptoms associated with chewing. |
12 months pot-op
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Neerav Goyal, Milton S. Hershey Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mouth Diseases
- Stomatognathic Diseases
- Nervous System Diseases
- Neoplasms by Site
- Neoplasms
- Head and Neck Neoplasms
- Skin Diseases
- Sweat Gland Diseases
- Salivary Gland Diseases
- Autonomic Nervous System Diseases
- Mouth Neoplasms
- Parotid Diseases
- Salivary Gland Neoplasms
- Skin and Connective Tissue Diseases
- Hyperhidrosis
- Parotid Neoplasms
- Sweating, Gustatory
Other Study ID Numbers
- 27627
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.